APA (7th ed.) Citation

MS, S., D, L., FJ, B., MP, B., DM, O., F, F., . . . A, G. (2026). Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer. Gynecologic oncology, 211, 79. https://doi.org/10.1016/j.ygyno.2026.06.010

Chicago Style (17th ed.) Citation

MS, Shahin, et al. "Updated Patient-reported Outcomes and the Effect of Disease Progression on Health-related Quality of Life in the PRIMA/ENGOT-OV26/GOG-3012 Trial of Niraparib First-line Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer." Gynecologic Oncology 211 (2026): 79. https://doi.org/10.1016/j.ygyno.2026.06.010.

MLA (9th ed.) Citation

MS, Shahin, et al. "Updated Patient-reported Outcomes and the Effect of Disease Progression on Health-related Quality of Life in the PRIMA/ENGOT-OV26/GOG-3012 Trial of Niraparib First-line Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer." Gynecologic Oncology, vol. 211, 2026, p. 79, https://doi.org/10.1016/j.ygyno.2026.06.010.